

## **ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES**

### **VACCINES FOR CHILDREN PROGRAM**

#### **VACCINES TO PREVENT MENINGOCOCCAL DISEASE**

*The purpose of this resolution is to update revaccination recommendations and to streamline the resolution through the use of links to published documents.*

*VFC resolution 10/07-2 is repealed and replaced by the following:*

#### **A. Polysaccharide Vaccine to Prevent Meningococcal Disease (MPSV4)**

##### **Eligible groups**

All children 2 through 18 years of age.

##### **Recommended Meningococcal Polysaccharide Vaccine Schedule**

The recommended schedule for meningococcal polysaccharide vaccine can found at:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm>

See Section B. Conjugate Vaccine to Prevent Meningococcal Disease for potential, limited use of MPSV4 for revaccination.

##### **Dosage Intervals for Meningococcal Polysaccharide Vaccine**

<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm>

See Section B. Conjugate Vaccine to Prevent Meningococcal Disease for potential, limited use of MPSV4 for revaccination.

##### **Recommended dosage**

The recommended dosage can be found in the package inserts available at

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833>

##### **Contraindications and Precautions**

Contraindications and Precautions can be found in the package inserts available at

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833>

#### **B. Conjugate Vaccine to Prevent Meningococcal Disease (MCV4)**

##### **Eligible groups**

All children 2 through 18 years of age.

## **Recommended Meningococcal Conjugate Vaccine Schedule**

The recommended schedule for meningococcal conjugate vaccine can be found at:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm>

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a3.htm>

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5648a4.htm>

Revaccination is recommended for children at increased risk of meningococcal disease, including:

- Persons with persistent complement component deficiencies (inherited or chronic deficiencies such as C3, properdin, factor D, or late complement components )
- Persons with anatomic or functional asplenia
- Persons infected with HIV
- Frequent travelers to or people living in areas with high rates of meningococcal disease (African meningitis belt)

## **Dosage Intervals for Meningococcal Conjugate Vaccine**

<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm>

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a3.htm>

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5648a4.htm>

- Children through age 18 years who received their first dose of MCV4 or MPSV4 at ages 2-6 years and remain at increased risk for meningococcal disease should receive an additional dose of MCV4 at 3 years after their first dose.
- Children through age 18 years who received a dose of MCV4 or MPSV4 after age 6 and remain at increased risk for meningococcal disease should receive an additional dose of MCV4 at 5 years after their previous dose.
- MCV4 is preferred for revaccination, but MPSV4 is an acceptable substitute for persons with precautions or contraindications to MCV4 vaccine.

## **Recommended dosage**

Recommended dosage can be found in the package inserts available at

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833>

## **Contraindications and Precautions**

Contraindications and Precautions can be found in the package inserts available at

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833>

[If an ACIP recommendation or notice regarding meningococcal vaccination is published within 12 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: June 24, 2009.

This document can be found on the CDC website at:

<http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/1007mening-mcv.pdf>